Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 42%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is poised to benefit from its robust therapeutic portfolio, led by Keytruda in immuno-oncology and Gardasil in vaccines. With the acquisition of Terns, Merck has solidified its position in the competitive landscape for treatment options in liver diseases and has potential blockbuster drugs in its pipeline with advancements in Terns `s therapy. The company's successful execution of its growth strategy along with a strong financial position and a steady dividend history, make it a long-term investment opportunity for investors seeking stable returns.

Bears say

Merck & Co is facing several challenges as the company approaches its second quarter earnings. Key factors shaping the quarter include moderate growth of Keytruda in the US and ongoing pricing headwinds in international markets, along with expected pressure on sales of Januvia/Janumet due to IRA pricing and increased competition. However, the company's pipeline and upcoming catalysts, such as full data releases for Islatravir + Lenacapavir and potential FDA approval for enlicitide, suggest potential for growth. Additionally, the company's diverse portfolio, global presence, and continued investment in pipeline development may mitigate these challenges and position Merck for long-term success.

Merck (MRK) has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 42% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 19 analysts, Merck (MRK) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $131.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $131.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.